Ogilvy & Mather has won at least an additional £7 million in
Glaxo SmithKline business in the UK from the rival roster agencies Grey
Worldwide and McCann-Erickson.
O&M has taken the Macleans toothpaste account, worth more than £4
million in the UK, from Grey. It has also taken the Zantac and Zovirax
cold sore cream work from McCann in all countries that it is sold over
The account is worth £2 million in the UK.
Glaxo SmithKline has also unveiled plans to enter the premium fruit
juice market with a new brand, Plenty, to be launched later this year
with creative through Grey.
The roster realignment follows the merger of SmithKline Beecham and
Glaxo Wellcome at the end of last year and the subsequent acquisition of
Block Drug. The changes come into effect from January 2002.
A press release said: "Grey Worldwide will be responsible for all former
Block Drug Sensodyne and Denture Care accounts with the exception of the
UK and Japan where the incumbent agencies, PTK and Asatsu DK
respectively, will be retained.
"Ogilvy & Mather will be appointed to handle the Zovirax, Zantac,
Beconase and Eumovate brands in all countries where these products are
marketed in over-the-counter form. O&M will also gain two oral care
assignments: Macleans in the UK and Iodosan in Italy."
Over-the-counter medicine accounts in the US will be consolidated across
four agencies - Grey, Publicis, Arnold McGrath and Creative Advertising
Services. The Phazyme brand will transfer from Grey to Publicis, Balmex
will move from Grey to CAS and Citrucel will move from O&M to Arnold